The changing landscape in the treatment of metastatic castration-resistant prostate cancer

被引：33

作者：

El-Amm, Joelle ^{[1
]}

Aragon-Ching, Jeanny B. ^{[1
]}

机构：

[1] George Washington Univ, Med Ctr, Dept Med, Div Hematol & Oncol, Washington, DC 20037 USA

来源：

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2013年 / 5卷 / 01期

关键词：

Androgen deprivation therapy; chemotherapy; metastatic castration-resistant prostate cancer; vaccine therapy; MITOXANTRONE PLUS PREDNISONE; RANDOMIZED PHASE-II; SIPULEUCEL-T; DOUBLE-BLIND; ANTITUMOR-ACTIVITY; BONE METASTASES; SURVIVAL; DOCETAXEL; MEN; TRIAL;

D O I：

10.1177/1758834012458137

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

The past few years have brought increasing advances in the therapeutic management of metastatic castration-resistant prostate cancer with the approval of several agents, including vaccine therapy with sipuleucel-T, second-line chemotherapy with cabazitaxel, the bone-targeted pharmaceutical denosumab, and the novel antiandrogen therapy abiraterone acetate. There are ongoing developments with other agents in the pipeline such as MDV3100 and alpharadin that have shown promising results. This review describes the clinical trials that brought about the drug approvals of various agents and offers some insights regarding a rational approach to optimal treatment sequencing for these drugs since national guidelines are currently lacking.

引用

页码：25 / 40

页数：16

共 67 条

[1]

Aragon-Ching Jeanny B, 2007, Cancer Ther, V5A, P151

[2]

Unravelling the role of denosumab in prostate cancer [J].

Aragon-Ching, Jeanny B. .

LANCET, 2011, 377 (9768) :785-786

[3]

Higher Incidence of Osteonecrosis of the Jaw (ONJ) in Patients with Metastatic Castration Resistant Prostate Cancer Treated with Anti-Angiogenic Agents [J].

Aragon-Ching, Jeanny B. ;

Ning, Yang-Min ;

Chen, Clara C. ;

Latham, Lea ;

Guadagnini, Jean-Pierre ;

Gulley, James L. ;

Arlen, Philip M. ;

Wright, John J. ;

Parnes, Howard ;

Figg, William D. ;

Dahut, William L. .

CANCER INVESTIGATION, 2009, 27 (02) :221-226

[4]

Optimizing the use of docetaxel in men with castration-resistant metastatic prostate cancer [J].

Armstrong, A. J. ;

George, D. J. .

PROSTATE CANCER AND PROSTATIC DISEASES, 2010, 13 (02) :108-116

[5]

A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: A TAX327 study analysis [J].

Armstrong, Andrew J. ;

Garrett-Mayer, Elizabeth S. ;

Yang, Yi-Chun Ou ;

de Wit, Ronald ;

Tannock, Ian F. ;

Eisenberger, Mario .

CLINICAL CANCER RESEARCH, 2007, 13 (21) :6396-6403

[6]

Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer [J].

Attard, G ;

Belldegrun, AS ;

de Bono, JS .

BJU INTERNATIONAL, 2005, 96 (09) :1241-1246

[7]

New Therapies for Castration-Resistant Prostate Cancer: Efficacy and Safety [J].

Beltran, Himisha ;

Beer, Tomasz M. ;

Carducci, Michael A. ;

de Bono, Johann ;

Gleave, Martin ;

Hussain, Maha ;

Kelly, William K. ;

Saad, Fred ;

Sternberg, Cora ;

Tagawa, Scott T. ;

Tannock, Ian F. .

EUROPEAN UROLOGY, 2011, 60 (02) :279-290

[8]

Androgen Receptor Expression in Prostate Cancer Cells Is Suppressed by Activation of Epidermal Growth Factor Receptor and ErbB2 [J].

Cai, Changmeng ;

Portnoy, David C. ;

Wang, Hongyun ;

Jiang, Xinnong ;

Chen, Shaoyong ;

Balk, Steven P. .

CANCER RESEARCH, 2009, 69 (12) :5202-5209

[9]

Listening to Provenge - What a Costly Cancer Treatment Says about Future Medicare Policy [J].

Chambers, James D. ;

Neumann, Peter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (18) :1687-1689

[10]

Chi KN, 2012, J CLIN ONCOL, V30

← 1 2 3 4 5 6 7 →